Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Raffaele Palmieri
Observed names:
Palmieri, Raffaele,
R. Palmieri,
Raffaele PALMIERI
Institutions:
University of Rome Tor Vergata,
Policlinico Tor Vergata
Observed institutions:
University of Siena,
University of Rome Tor Vergata,
University of Washington,
Azienda Ospedaliera San Giovanni Addolorata,
Fred Hutch Cancer Center,
Azienda Ospedaliera S.Giuseppe Moscati,
Policlinico Tor Vergata,
Sapienza University of Rome
show all 8
ORCID:
0000-0003-2855-8121
Observed ORCID:
0000-0003-2855-8121
OpenAlex ID:
A5063271841
Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML
2022
·
Gabrielle Paras
, Linde M. Morsink
, et al.
·
Blood
·
94
PDF
Therapeutic Choice in Older Patients with Acute Myeloid Leukemia: A Matter of Fitness
2020
·
Raffaele Palmieri
, Giovangiacinto Paterno
, et al.
·
Cancers
·
70
PDF
Accuracy of SIE/SIES/GITMO Consensus Criteria for Unfitness to Predict Early Mortality After Intensive Chemotherapy in Adults With AML or Other High-Grade Myeloid Neoplasm
2020
·
Raffaele Palmieri
, Megan Othus
, et al.
·
Journal of Clinical Oncology
·
60
Baseline T-lymphocyte subset absolute counts can predict both outcome and severity in SARS-CoV-2 infected patients: a single center study
2021
·
Marco Iannetta
, Francesco Buccisano
, et al.
·
Scientific Reports
·
43
PDF
Conditioning Intensity, Pre-Transplant Flow Cytometric Measurable Residual Disease, and Outcome in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation
2020
·
Linde M. Morsink
, Brenda M. Sandmaier
, et al.
·
Cancers
·
43
PDF
Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
2025
·
Adriano Venditti
, Raffaele Palmieri
, et al.
·
Blood Advances
·
38
PDF
Predictors of Early Thrombotic Events in Adult Patients with Acute Myeloid Leukemia: A Real-World Experience
2022
·
Giovangiacinto Paterno
, Raffaele Palmieri
, et al.
·
Cancers
·
32
PDF
Clinical relevance of an objective flow cytometry approach based on limit of detection and limit of quantification for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial
2022
·
Francesco Buccisano
, Raffaele Palmieri
, et al.
·
Haematologica
·
24
PDF
Measurable Residual Disease (MRD) as a Surrogate Efficacy-Response Biomarker in AML
2023
·
Elisa Meddi
, Arianna Savi
, et al.
·
International Journal of Molecular Sciences
·
23
PDF
Vitamin C Deficiency in Patients With Acute Myeloid Leukemia
2022
·
Tiziana Ottone
, Isabella Faraoni
, et al.
·
Frontiers in Oncology
·
22
The ISTH DIC-score predicts early mortality in patients with non-promyelocitic acute myeloid leukemia
2024
·
Giovangiacinto Paterno
, Raffaele Palmieri
, et al.
·
Thrombosis Research
·
20
PDF
Real‐world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts
2023
·
Luca Lanino
, Francesco Restuccia
, et al.
·
American Journal of Hematology
·
20
Increased Plasma Levels of lncRNAs LINC01268, GAS5 and MALAT1 Correlate with Negative Prognostic Factors in Myelofibrosis
2021
·
Sebastian Fantini
, Sebastiano Rontauroli
, et al.
·
Cancers
·
18
Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML)
2024
·
Eduardo Rodríguez-Arbolí
, Megan Othus
, et al.
·
Leukemia
·
17
PDF
The Response to Oxidative Damage Correlates with Driver Mutations and Clinical Outcome in Patients with Myelofibrosis
2022
·
Elena Genovese
, Margherita Mirabile
, et al.
·
Antioxidants
·
17
PDF
Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms
2016
·
Luigi Gugliotta
, Alessandra Iurlo
, et al.
·
Leukemia Research
·
16
Fever of Unknown Origin and Multidrug-resistant Organisms Colonization in Aml Patients.
2023
·
Luca Guarnera
, Gentiana Elena Trotta
, et al.
·
Mediterranean Journal of Hematology and Infectious Diseases
·
15
PDF
An evaluation of enasidenib for the treatment of acute myeloid leukemia
2019
·
Maria Ilaria Del Principe
, Giovangiacinto Paterno
, et al.
·
Expert Opinion on Pharmacotherapy
·
15
Risk-adapted MRD-directed therapy for young adults with acute myeloid leukemia: 6-year update of the GIMEMA AML1310 trial
2024
·
Adriano Venditti
, Alfonso Piciocchi
, et al.
·
Blood Advances
·
14
PDF
The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study
2021
·
Salvatore Leotta
, Uros Markovic
, et al.
·
Annals of Hematology
·
14
Clinical Relevance of- Limit of Detection (LOD) - Limit of Quantification (LOQ) - Based Flow Cytometry Approach for Measurable Residual Disease (MRD) Assessment in Acute Myeloid Leukemia (AML)
2020
·
Raffaele Palmieri
, Alfonso Piciocchi
, et al.
·
Blood
·
14
Navigating acute myeloid leukemia towards better outcomes: Treatment pathways and challenges for patients ineligible for intensive chemotherapy
2025
·
Raffaele Palmieri
, Anna Candoni
, et al.
·
Blood Reviews
·
13
CD99 as a novel therapeutic target on leukemic progenitor cells in FLT3-ITDmut AML
2022
·
Serena Travaglini
, Tiziana Ottone
, et al.
·
Leukemia
·
13
ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol
2021
·
Francesco Buccisano
, Raffaele Palmieri
, et al.
·
Blood Advances
·
12
PDF
Real World Study on the Best CPX ‐351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation
2025
·
Fabio Guolo
, Luana Fianchi
, et al.
·
American Journal of Hematology
·
11
PDF
Show more works
View as search
Works count:
109
Citation count:
895
H-index:
16
I10-index:
26
Year
Topic
Type